Kyntra Bio, Inc.

NasdaqGS:KYNB Stock Report

Market Cap: US$37.0m

Kyntra Bio Management

Management criteria checks 2/4

Kyntra Bio's CEO is Thane Wettig, appointed in Jul 2023, has a tenure of 2.5 years. total yearly compensation is $2.64M, comprised of 25.2% salary and 74.8% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $191.80K. The average tenure of the management team and the board of directors is 1.1 years and 7.1 years respectively.

Key information

Thane Wettig

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage25.17%
CEO tenure2.5yrs
CEO ownership0.5%
Management average tenure1.1yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

Is FibroGen (NASDAQ:FGEN) A Risky Investment?

Dec 16
Is FibroGen (NASDAQ:FGEN) A Risky Investment?
User avatar

Simplifying Operations And Advancing FG-3246 Will Secure Future Success

Strategic cost reductions and the sale of FibroGen China enhance financial stability, extending cash runway and potentially boosting overall financial performance.

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

Apr 08
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

Feb 21
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Dec 25
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19
The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 06

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

May 28

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

May 07
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22
FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18
Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

CEO Compensation Analysis

How has Thane Wettig's remuneration changed compared to Kyntra Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$52m

Jun 30 2025n/an/a

-US$87m

Mar 31 2025n/an/a

-US$121m

Dec 31 2024US$3mUS$665k

-US$153m

Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$255m

Mar 31 2024n/an/a

-US$295m

Dec 31 2023US$4mUS$573k

-US$323m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$322m

Mar 31 2023n/an/a

-US$307m

Dec 31 2022US$3mUS$535k

-US$294m

Sep 30 2022n/an/a

-US$362m

Jun 30 2022n/an/a

-US$220m

Mar 31 2022n/an/a

-US$281m

Dec 31 2021US$3mUS$510k

-US$290m

Sep 30 2021n/an/a

-US$215m

Jun 30 2021n/an/a

-US$231m

Mar 31 2021n/an/a

-US$183m

Dec 31 2020US$4mUS$263k

-US$189m

Compensation vs Market: Thane's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD572.26K).

Compensation vs Earnings: Thane's compensation has been consistent with company performance over the past year.

CEO

Thane Wettig (59 yo)

2.5yrs
Tenure
US$2,642,113
Compensation

Mr. Thane Wettig serves as Director of Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) since October 2, 2023. He serves as Chief Executive Officer at Kyntra Bio, Inc. (formerly known as FibroGen, Inc.)...

Leadership Team

NamePositionTenureCompensationOwnership
Thane Wettig
CEO & Director2.5yrsUS$2.64m0.52%
$ 191.8k
David DeLucia
Senior VP & CFO1.1yrsUS$686.15k0.11%
$ 41.0k
John Alden
Corporate Secretary & General Counsel1yrno datano data
Gaia Vasiliver-Shamis
Director of IR & Communications - LifeSci Advisorsno datano datano data
1.1yrs
Average Tenure

Experienced Management: KYNB's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thane Wettig
CEO & Director2.3yrsUS$2.64m0.52%
$ 191.8k
Jeffrey Edwards
Independent Director10.3yrsUS$143.74k0.034%
$ 12.4k
Michael Kauffman
Directorless than a yearno datano data
James Schoeneck
Independent Chairman of the Board15.8yrsUS$189.36k0.98%
$ 362.5k
Maykin Ho
Independent Director7.1yrsUS$132.49k0.031%
$ 11.5k
7.1yrs
Average Tenure
64yo
Average Age

Experienced Board: KYNB's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/18 02:32
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyntra Bio, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Matthew KellerH.C. Wainwright & Co.
Xiaodong ZhangH.C. Wainwright & Co.